There is a new strategic blueprint for designing smarter early phase trials in oncology. Some outlets are reporting on partnerships and strategies related to clinical trials, including a research partnership between Bayer and Henry Ford Health, while others are discussing the use of minimum residual disease as a development strategy. However, it appears that not all reports are directly related to the topic, with some covering unrelated subjects such as autonomous baggage vehicles and smart mobility programs.